Overview

Acting as an interdisciplinary solution to reversing obesity treatment, Protheragen focuses on addressing a full spectrum of biological mechanisms in the fight against obesity. In parallel, we provide services focused on building therapies - including the development of small molecule drugs; gene therapy and cell therapy products for hematopoietic stem cells (HSCs), induced pluripotent stem cells (iPSC), or embryonic stem cells (ESCs); antibody-based agents against novel gene/protein targets; as well as advanced nano-therapies. This includes both in vivo and in vitro models, pharmacokinetics (PK), bioanalysis, and safety assessments supporting preclinical studies. We also supply analyses on the causes of obesity, diagnostic tests and prediction capacity for obesity, identification studies into biomarkers of this condition; research in fields such as gene manipulation assays (gene editing), microbiota-related diseases, pathobiology mechanisms, and treatment methods to promote weight loss.

Fig.1 The major cause of obesity is a positive energy balance between energy intake and energy expenditure leading to meta-inflammation, and the anti-obesity effects of anthocyanins. (Ngamsamer, et al., 2022)

Comprehensive Solutions for the Development of Anti-Obesity Therapeutics at Protheragen

Protheragen's anti-obesity solutions focus on key areas like identifying targets, therapy development, and conducting preclinical studies, supported by a comprehensive range of services. These efforts assist clients in the development and preclinical evaluation of anti-obesity drugs, helping advance their projects from discovery to clinical readiness.

• Targets

  Several critical biological targets for developing anti-obesity therapeutics, and each target type represents a different approach to managing obesity at a molecular level.

  By targeting hormones and peptides, we aim to modulate hunger signals and energy expenditure. Targeting receptors like melanocortin 4 receptor (MC4R) help correct dysfunctional signaling pathways linked to obesity. Additionally, Protheragen's strategy includes targeting enzymes and proteins that regulate metabolic processes to encourage weight loss, and metabolic regulators to shift the body from fat storage to fat utilization. Furthermore, we address obesity-related inflammation by targeting signaling molecules that affect metabolic health.

• Anti-Obesity Therapy Development

  Protheragen is advancing the development of various anti-obesity therapies that address the complex etiology of obesity.

  Protheragen's anti-obesity therapeutic development spans several cutting-edge approaches. Our work in small molecule drug development uses high-throughput screening and structure-based design to inhibit enzymes and receptors involved in fat accumulation. Gene therapy addresses genetic factors contributing to obesity, while cell therapy, including stem cells, offers innovative treatment options. In antibody therapy, Protheragen focuses on engineering monoclonal antibodies to target hormones like leptin or cytokines such as IL-6 to regulate appetite and inflammation. Additionally, tissue engineering explores bioengineered tissues that can burn fat or restore normal metabolic functions. Finally, nano-therapy provides targeted drug delivery to adipose tissue or the brain, improving treatment efficacy with reduced side effects.

  

  Small Molecule Drug Development

  

  Gene Therapy Development

  

  Cell Therapy Development

  

  Antibody Therapy Development

  

  Tissue Engineering Therapy Development

  

  Nanotherapy Development

• Preclinical Studies of Anti-Obesity Therapeutics

  Preclinical studies are critical for evaluating the safety and efficacy of potential anti-obesity treatments before they reach clinical trials.

  Protheragen utilizes a comprehensive approach to anti-obesity therapeutic development, employing various obesity models, including genetically modified mice and diet-induced obese rats, to evaluate treatment efficacy. Our pharmacodynamic studies focus on how therapies affect appetite, energy expenditure, and body weight, while pharmacokinetic studies ensure proper absorption, distribution, metabolism, and excretion of drugs. Through bioanalysis, we measure drug levels in biological samples to fine-tune formulations for optimal effectiveness. Additionally, Protheragen prioritizes safety by conducting thorough assessments to identify potential adverse effects, such as cardiotoxicity or neurotoxicity, ensuring the safe development of anti-obesity therapies.

  

  Obesity Models

  

  Pharmacodynamic Study

  

  Pharmacokinetic Study

  

  Bioanalysis

  

  Safety Assessment

Our Services

Protheragen offers a wide range of services to support obesity research and treatment, providing essential tools and data for developing effective therapies.

Protheragen offers a range of services to address the complex causes and treatment of obesity. Our obesity causation analysis includes genetic testing, metabolic assessments, and environmental risk evaluations to identify contributing factors. We provide diagnostic tests for obesity-related genetic mutations and metabolic markers, as well as an obesity prediction service using advanced algorithms. Protheragen also focuses on biomarker identification, pinpointing novel proteins or metabolites linked to obesity, and offers targeted gene editing with technologies. Our microbiota research examines gut bacteria's role in obesity, while pathobiology research explores molecular changes like inflammation. Additionally, our weight loss and management services include dietary, behavioral, and pharmacological interventions.

Applications

• The small molecule drugs we developed are used in preclinical research and evaluated the effect of obesity control.
• Gene editing technologies can be applied to treat genetic forms of obesity by correcting mutations in genes like MC4R. Similarly, cell therapies, including CAR-T and stem cell therapy, offer novel approaches to modify immune responses and regenerate tissues affected by obesity, which could be groundbreaking in personalized medicine research.
• Our tests are crucial for detecting early signs of obesity-related metabolic disorders, allowing for timely intervention and monitoring to prevent the progression of the disease.
• Our solutions extend to the development of comprehensive weight management programs that incorporate pharmacotherapy, nutritional counseling, and behavioral interventions.

Advantages

• Protheragen's anti-obesity solutions cover all stages of obesity management, from prevention and diagnosis to treatment research and maintenance.
• The use of gene therapy, targeted editing, and predictive analysis allows Protheragen to offer personalized treatment plans for obesity research.
• Protheragen is at the forefront of developing cutting-edge therapies, including gene editing, nanotechnology, and antibody therapies.
• The extensive preclinical testing conducted by Protheragen ensures that their anti-obesity therapies are both safe and effective.

Publication

Frequently Asked Questions

What future developments can we expect from Protheragen in the field of obesity treatment?

Protheragen is committed to ongoing research and innovation in the field of obesity treatment:

• Continued research into novel targets, including unexplored receptors and signaling molecules, could lead to new therapies.
• Protheragen expands its portfolio of gene and cell therapies, potentially offering cures for genetic forms of obesity.
• As research on the gut microbiota progresses, Protheragen develops new microbiota-based therapies that could revolutionize obesity treatment.

What types of anti-obesity therapy development services does Protheragen offer?

Protheragen offers a comprehensive range of anti-obesity therapies development, including:

• Small molecule drugs: These are designed to target specific metabolic pathways and receptors to reduce appetite, increase energy expenditure, or inhibit fat absorption.
• Gene therapy: Utilizing advanced techniques, Protheragen develops personalized treatment programs for genetic factors that lead to obesity.
• Cell therapy: This includes stem cell therapies aimed at regenerating tissues and modulating immune responses to combat obesity.
• Antibody therapy: Monoclonal antibodies are used to target specific proteins or cytokines involved in the regulation of metabolism and inflammation.
• Tissue engineering and nano-therapy: These innovative therapies involve the use of bioengineered tissues and nanoparticles for targeted drug delivery and metabolic regulation.

At Protheragen, our anti-obesity solutions are comprehensive, addressing the issue of obesity from multiple angles, including molecular targets, innovative therapies, rigorous preclinical testing, and extensive supportive services. Please feel free to contact us to discover how we support your research and development needs.

All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.

• Anti-Obesity Therapy Development
• Our Services
• Preclinical Studies of Anti-Obesity Therapeutics
• Targets for Developing Anti-Obesity Therapeutics